Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011;16(11):1600-3.
doi: 10.1634/theoncologist.2011-0229. Epub 2011 Oct 3.

Improvement in survival of older adults with multiple myeloma: results of an updated period analysis of SEER data

Dianne Pulte  1 , Adam Gondos, Hermann Brenner
Affiliations

Improvement in survival of older adults with multiple myeloma: results of an updated period analysis of SEER data

Dianne Pulte et al. Oncologist. 2011.

Abstract

Background: Treatment of multiple myeloma has changed significantly over the past several years with clinical trials reporting superior survival results using newer agents. Previous work has shown that the survival rate has improved for younger, but not older, patients with myeloma. Here, we update survival estimates for patients with myeloma in the early 21st century to determine whether continued improvement can be seen on a population level and whether or not it now extends to older patients.

Methods: Using period analysis to examine data from the Surveillance, Epidemiology, and End Results database, we estimate changes in the 5- and 10-year relative survival rates (RSRs) from 1998-2002 to 2003-2007.

Results: The 5- and 10-year RSRs have improved for patients with myeloma overall, from 32.8% and 15% in 1998-2002 to 40.3% and 20.8%, respectively, in 2003-2007. The greatest improvements were observed for patients aged 15-44 years, with 5- and 10-year RSRs reaching >70% and ~50%, respectively, but improvements were also seen for patients aged >70 years.

Conclusion: Overall, survival continues to improve for patients with myeloma, including older patients, suggesting that newer treatment options continue to make a population-wide impact.

PubMed Disclaimer

Conflict of interest statement

Disclosures: Dianne Pulte: None; Adam Gondos: None; Hermann Brenner: None.

References

    1. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277–300. - PubMed
    1. Brenner H, Gondos A, Pulte D. Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood. 2008;111:2521–2526. - PubMed
    1. Wijermans P, Schaafsma M, Termorshuizen F, et al. Phase III study of the value of thalidomide added to melphelan plus prednisone in elderly patients with newly diagnosed multiple myeloma: The HOVON 49 Study. J Clin Oncol. 2010;28:3160–3166. - PubMed
    1. San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008;359:906–917. - PubMed
    1. DCCPS, Surveillance Research Program, Cancer Statistics Branch. Bethesda. MD: National Cancer Institute; 2011. [accessed September 28, 2011]. Surveillance, Epidemiology, and End Results (SEER) Program Limited Use Data (1973–2008). Released April, 2011 based on November 2010 submission. Available at www.seer.cancer.gov.